In some RS cases (e.g., RSVR3, RS1050, RS1316), MCL-1, BCL-xL, and BFL-1 exerted a prominent role in protecting cancer cells from apoptosis, suggesting their direct targeting might be effective and outperform BCL-2 antagonism. Here, BCL2 is linked to cancer.